H.C. Wainwright lowered the firm’s price target on Cardiff Oncology (CRDF) to $10 from $18 and keeps a Buy rating on the shares following the Q2 report. The firm reduced its probability of approval for onvansertib to 25% from 40%, seeing a higher risk profile following the most recent data.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Largest borrow rate increases among liquid names
- Promising Outlook for Cardiff Oncology’s Onvansertib Despite Phase II Trial Challenges
- Cardiff Oncology Reports Q2 2025 Financial Results
- Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
- Cardiff Oncology announces data from CRDF-004 trial